The PROTID investigators responded that their first global randomised controlled trial will address that very issue; evaluating the efficacy and potential impact of preventive treatment of latent tuberculosis infection (LTBI) targeted at people living with Diabetes Mellitus (DM).
For the full article visit this page.
